- You can view the full Eli Lilly and Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Shares of Biogen soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked and Eli Lilly's study failed.
Jim Cramer says investors need to be careful speculating on Biogen's treatment for Alzheimer's while investors came away from Broadcom's earnings with a more positive vibe on Apple.
Lilly's sola study did not reduce amyloid plaques in the brain, adding to the likelihood that Biogen's late-stage Alzheimer's study will prove successful.